Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced a new agreement to expand access to Reyataz® (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.
Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control
- Details
- Category: Novo Nordisk
Ultra-long-acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego.
Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation awarded five grants totaling $1.5 million to organizations that will empower African American women with type 2 diabetes to better manage their disease while also leveraging their standing as leaders in their families and communities to influence the health of those around them.
Merck: Regulatory Update on Cladribine Tablets
- Details
- Category: Merck Group
Merck KGaA announced that following feedback from regulatory authorities the company has decided to no longer pursue the global approval process of Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS).
Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) announced the 34 science teachers in the United States, Canada and Puerto Rico who are this year's recipients of the 19th annual Amgen Award for Science Teaching Excellence.
Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health"
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Ashoka will launch a three-year global initiative to improve health in communities around the world.The "Making More Health" initiative will promote healthy individuals, families and communities by identifying and supporting the most promising solutions to challenge health problems.
Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases
- Details
- Category: Abbott
Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis.
More Pharma News ...
- FDA panel endorses efficacy but not safety of Novartis drug ACZ885 for gouty arthritis
- Pivotal study showed vismodegib helped shrink tumours or heal lesions
- Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform
- Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia
- AstraZeneca extends its investment in Russia
- Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets
- GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China